E/C/F/TAF Placebo

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

Acquired Immunodeficiency SyndromeHIVHIV Infections

Phase 2

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01497899

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2011-12-28End: 2016-08-22Updated: 2018-11-19

Phase 3

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

CompletedNCT01780506

Gilead SciencesHIV, HIV Infections

Start: 2012-12-26End: 2017-09-06Updated: 2018-11-19

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

CompletedNCT01797445

Gilead SciencesHIV, HIV Infections

Start: 2013-03-12End: 2018-10-03Updated: 2020-03-02

Related Papers

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

2015-04-15429 citations